Inhibition of Aromatase With CGS 16949A in Postmenopausal Women*
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Potent, specific, and nontoxic inhibitors of aromatase would be useful for experimental studies and for use in the treatment of breast cancer and other disorders. We evaluated the effects of CGS 16949A, a nonsteroidal inhibitor of aromatase activity, in 12 postmenopausal women with breast cancer by measuring plasma and/or urinary androgens and estrogens after oral administration of CGS 16949A at doses ranging from 0.6-16 mg daily; each dose was given for 2 weeks. The 0.6-mg daily dose partially lowered estrogen levels, and maximum reduction occurred at doses of 2-16 mg daily. The fall in plasma and urinary estrogens without a concomitant fall in plasma androgens confirmed the blockade of aromatase activity. The degree of estrogen reduction was greatest for urinary estrone [to 27 +/- 3% (+/- SE) of basal], followed in order by plasma estrone sulfate (30 +/- 4%), plasma estrone (32 +/- 6%), urine estradiol (45 +/- 5%), and plasma estradiol (65 +/- 5%). Use of gas liquid chromatography-mass spectrometry techniques revealed similar patterns of reduction in catechol estrogens, estriol, and total urinary estrogens, suggesting that CGS 16949A does not alter the pathways of estrogen metabolism. The degree of estrogen reduction was remarkably similar to that caused with aminoglutethimide. At doses of 4-16 mg daily, CGS 16949A inhibited the C21-hydroxylase enzyme as well, based on concomitant rises in plasma androstenedione, testosterone, and 17 alpha-hydroxyprogesterone. This effect was insufficient to lower urinary cortisol excretion during the study. However, a statistically significant blunting of plasma cortisol responses to ACTH occurred with the 16-mg daily dose. No changes in plasma dehydroepiandrosterone sulfate levels or in thyroid, hematological, liver, or renal parameters were found. No significant side-effects of the medication were encountered. CGS 16949A appears to be a specific inhibitor of aromatase at doses below 4 mg daily and to lack apparent side-effects or toxic actions at doses up to 16 mg daily. This agent shows promise as a potent aromatase inhibitor for physiological and clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Source of Estrogen Production in Postmenopausal Women1
GRODIN, J. M., SIITERI, P. K., & MACDONALD, P. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-36-2-207 · Cited by 959
MacDonald, P. C., Edman, C. D., Hemsell, D. L., Porter, J. C., & Siiteri, P. K. (1978) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(78)90287-9 · Cited by 440
The use of ketoconazole as an inhibitor of steroid production
Oates, J. A., Wood, A. J. J., & Sonino, N. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709243171307 · Cited by 395
Aromatization of Androgens by Muscle and Adipose Tissue in Vivo*
LONGCOPE, C., PRATT, J. H., STEPHEN, H. S., & FINEBERG, S. E. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-46-1-146 · Cited by 392
CONVERSION OF ANDROSTENEDIONE TO ESTRONE BY HUMAN FAT TISSUE
Schindler, A. E., Ebert, A., & Friedrich, E. (1972) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-35-4-627 · Cited by 319
Aromatization of Androgens by Human Abdominal and Breast Fat Tissue1
NIMROD, A., & RYAN, K. J. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-40-3-367 · Cited by 314
Cited by
Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P., & Lønning, P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.531 · Cited by 336
Arimidex�: A potent and selective fourth-generation aromatase inhibitor
Plourde, P. V., Dyroff, M., & Dukes, M. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00682745 · Cited by 258
Inhibition of Cytochrome P450 Enzymes
Correia, M. A., & Hollenberg, P. F. (2015) · Cytochrome P450 · doi:10.1007/978-3-319-12108-6_5 · Cited by 257
(1993) · PubMed · Cited by 130
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women
Iveson, T. J. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.2.324 · Cited by 82
Metadata
- Authors
- SANTEN, R. J., DEMERS, L. M., ADLERCREUTZ, H., HARVEY, H., SANTNER, S., SANDERS, S., & LIPTON, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1989-01
- Volume
- 68
- Issue
- 1
- Pages
- 99-106
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2089230721
- Cited by
- 100
- References
- 6
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Aromatase With CGS 16949A in Postmenopausal Women*. https://app.cochat.ai/papers/10.1210/jcem-68-1-99
- The paper
- SANTEN, R. J., DEMERS, L. M., ADLERCREUTZ, H., HARVEY, H., SANTNER, S., SANDERS, S., & LIPTON, A. (1989). Inhibition of Aromatase With CGS 16949A in Postmenopausal Women*. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem-68-1-99
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.